

Correction

Correction: Kao et al. RNF8–CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. *J. Pers. Med.* 2021, 11, 655

Chieh-Ni Kao ^{1,2}, Sin-Hua Moi ³ , Ming-Feng Hou ^{2,*} , Chi-Wen Luo ² , Fang-Ming Chen ² 
and Mei-Ren Pan ^{1,4,*} 

- ¹ Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; jennykao0320@gmail.com
 - ² Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan; cwlo0623@gmail.com (C.-W.L.); fmc5464@gmail.com (F.-M.C.)
 - ³ Center of Cancer Program Development, E-Da Cancer Hospital, I-Shou University, Kaohsiung 824, Taiwan; moi9009@gmail.com
 - ⁴ Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan
- * Correspondence: mifeho@kmu.edu.tw (M.-F.H.); mrpan@cc.kmu.edu.tw (M.-R.P.); Tel.: +886-7-312-1101-6060 (M.-F.H.); +886-7-312-1101-5092-94 (M.-R.P.); Fax: +886-7-321-8309 (M.-R.P.)



Citation: Kao, C.-N.; Moi, S.-H.; Hou, M.-F.; Luo, C.-W.; Chen, F.-M.; Pan, M.-R. Correction: Kao et al. RNF8–CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. *J. Pers. Med.* 2021, 11, 655. *J. Pers. Med.* **2022**, 12, 466. <https://doi.org/10.3390/jpm12030466>

Received: 23 February 2022

Accepted: 7 March 2022

Published: 15 March 2022


Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


The authors would like to make corrections to a recently published paper [1]. The reason for the correction is that Figure 5 was misplaced with all TNBC data, not TNBC LN (+) data. In addition, typo errors and citation errors were shown in Sections 3.1 and 3.2, and Reference No. 6.

Original Figure 5:



We would like it to be corrected as shown below.

1. New Figure 5:



2. The result of Section 3.1. Clinicopathological Characteristics and Progression of Breast Cancer.

A total of 264 LN+ patients, with a median age of 56 years.

3. The result of Section 3.2. A Significant Correlation Among RNF8, SNAI1, and CDH1 mRNA Expression in Patients with Breast Cancer.

SNAI1 showed a significant positive correlation (r value = 0.185).

4. The right reference No. 6 is: Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. *J. Clin. Investig.* **2009**, *119*, 1420–1428. <http://doi.org/10.1172/jci39104>.

These changes do not change the results or conclusions of our paper. The authors would like to apologize to readers of *JPM* for this error. The published version will be updated on the article webpage, with a reference to this correction notice.

Reference

- Kao, C.-N.; Moi, S.-H.; Hou, M.-F.; Luo, C.-W.; Chen, F.-M.; Pan, M.-R. RNF8–CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. *J. Pers. Med.* **2021**, *11*, 655. [[CrossRef](#)] [[PubMed](#)]